Arzerra (Ofatumumab): Uses, Side Effects & Warnings

Key Takeaways

• Arzerra (Ofatumumab) is an anti-CD20 monoclonal antibody approved for use in chronic lymphocytic leukemia (CLL).
• It is indicated for previously untreated CLL and for relapsed or refractory CLL in patients who cannot tolerate certain chemotherapy regimens.
• Common side effects include infusion reactions, neutropenia, and increased infection risk.
• Serious warnings include the risk of hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), and severe infusion reactions.
• Patients should inform their healthcare provider about all medications, vaccinations, and existing conditions before beginning treatment.

What Is Arzerra (Ofatumumab) and How Does It Work?

Ofatumumab is a fully human monoclonal antibody that targets the CD20 antigen found on the surface of B-lymphocytes, including malignant B-cells associated with CLL. By binding to a distinct epitope on CD20 — one that differs from the binding site used by other anti-CD20 therapies — ofatumumab triggers immune-mediated destruction of these cancerous cells through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This precise mechanism allows it to selectively attack leukemic B-cells while sparing most other cell types.

The drug was developed by GlaxoSmithKline and received U.S. Food and Drug Administration (FDA) approval for CLL-related indications. As a fully human antibody, it is designed to minimize immunogenic reactions that can occur with chimeric or murine-derived antibodies. This characteristic made it a meaningful advancement in the class of ofatumumab monoclonal antibody treatments at the time of its clinical development.

CLL is one of the most common types of leukemia in adults in Western countries, accounting for approximately 25–30% of all leukemia diagnoses according to data referenced by the National Cancer Institute. Because it primarily affects older adults, treatment must balance efficacy with tolerability — an area where targeted biologic agents like ofatumumab offer distinct advantages over conventional chemotherapy alone.

Arzerra (Ofatumumab) Uses and Dosage in CLL Treatment

Arzerra ofatumumab CLL treatment is indicated in two primary clinical settings. First, it is approved in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Second, it is approved as a monotherapy for patients with CLL that is refractory to fludarabine and alemtuzumab, meaning the disease has not responded to or has progressed after both of these treatments.

The dosing regimen for Arzerra varies by indication. For previously untreated CLL in combination with chlorambucil, the approved regimen typically involves an initial dose followed by subsequent doses on a defined cycle schedule, administered intravenously by a healthcare professional in a clinical setting. For refractory CLL, a different multi-dose schedule applies, beginning with two initial doses administered one week apart, followed by additional doses given every four weeks. All doses are given as intravenous infusions, and patients must be premedicated before each infusion to reduce the risk of reactions.

Dosage adjustments may be required based on the patient’s tolerance of infusion-related reactions, laboratory values, or concurrent medical conditions. Clinicians determine the appropriate schedule based on disease stage and overall patient health. This information is consistent with FDA prescribing guidelines and should never be self-administered or adjusted without physician oversight.

Indication	Combination	Route of Administration
Previously untreated CLL (fludarabine-ineligible)	With chlorambucil	Intravenous infusion
Refractory CLL (post-fludarabine and alemtuzumab)	Monotherapy	Intravenous infusion

As a guide for patients and caregivers, the Arzerra ofatumumab patient medication guide provided by the manufacturer and dispensing pharmacy outlines infusion schedules, what to expect during treatment visits, and when to seek medical attention. Reviewing this guide thoroughly before and during treatment is strongly encouraged.

Ofatumumab Side Effects, Warnings, and Safety Precautions

Like all cancer therapies, Arzerra carries a range of potential adverse effects. Ofatumumab side effects in chronic lymphocytic leukemia patients span from mild and manageable to serious and potentially life-threatening. Understanding these effects helps patients report symptoms promptly and supports clinicians in making timely treatment adjustments.

The most commonly reported side effects include infusion-related reactions, which may present as fever, chills, rash, low blood pressure, or shortness of breath — typically during or shortly after the infusion. Neutropenia, a reduction in white blood cells that increases infection susceptibility, is also frequently observed. Other common effects include fatigue, nausea, diarrhea, anemia, cough, and upper respiratory tract infections.

Serious adverse effects require immediate medical attention. These include severe infusion reactions, significant infections, and cardiac events. The FDA label for Arzerra includes several boxed warnings, which represent the most serious safety alerts:

• Hepatitis B virus (HBV) reactivation: Ofatumumab can cause HBV to reactivate in patients who carry the virus, sometimes resulting in fulminant hepatitis, liver failure, or death. All patients should be screened for HBV before starting treatment.
• Progressive multifocal leukoencephalopathy (PML): A rare but potentially fatal brain infection caused by the JC virus has been reported in patients receiving ofatumumab. Symptoms include new or worsening neurological changes.
• Severe infusion reactions: These can occur during or within 24 hours of infusion and may require dose interruption, medication, or permanent discontinuation of therapy.

Additional precautions noted in the ofatumumab Arzerra side effects and warnings profile include the risk of cytopenias (reductions in blood cell counts) persisting after treatment, intestinal obstruction, and immunization concerns. Live vaccines should generally be avoided during and after treatment, as ofatumumab suppresses B-cell function and immune response.

Monitoring During Arzerra Treatment

Regular laboratory monitoring is an essential part of safe ofatumumab therapy. Clinicians typically check complete blood counts (CBC) before each infusion cycle to assess neutrophil and platelet levels. Liver function tests and HBV screening are also performed at baseline and periodically during treatment. Patients should attend all scheduled monitoring appointments and report any unexpected symptoms between visits.

Drug Interactions and Immunosuppression Considerations

Arzerra can interact with other immunosuppressive agents, potentially intensifying the risk of infection or immune suppression. Concurrent use with other biologics or chemotherapy agents requires careful clinical oversight. Patients should disclose all current medications — including over-the-counter drugs and supplements — to their oncology team before beginning therapy.

Important Patient Information Before Taking Arzerra

Before initiating therapy, patients should undergo a thorough medical evaluation. The Arzerra drug uses dosage and safety warnings outlined in the prescribing information indicate that patients with active infections, compromised immune function, or a history of HBV require special consideration. Pregnancy status is also relevant, as ofatumumab may cause fetal harm and is not recommended during pregnancy. Effective contraception is advised for both women of childbearing potential and male patients with partners of childbearing potential.

Patients should inform their healthcare provider about any history of heart disease, lung conditions, or prior cancer treatments before beginning Arzerra. Since infusion reactions are most common during the first and second doses, patients are typically observed for an extended period following these early infusions. Premedications — such as acetaminophen, an antihistamine, and a corticosteroid — are generally administered before each dose to reduce reaction risk.

It is also important for patients to understand that Arzerra is administered exclusively in a clinical or hospital setting by trained healthcare professionals. It is not a medication taken at home, and all dosing decisions must be made by a qualified oncologist. Patients are encouraged to ask their treatment team about what to expect at each visit, how to recognize warning signs, and who to contact in the event of an emergency between treatment sessions.

Remaining engaged in treatment — including keeping all appointments, completing required lab work, and communicating openly about side effects — significantly contributes to the safety and effectiveness of the therapy. Support resources, including patient assistance programs and clinical pharmacists, can also help patients navigate the logistical and emotional aspects of CLL treatment with ofatumumab.

Frequently Asked Questions

Is Arzerra (Ofatumumab) used as a first-line treatment for CLL?

Arzerra is approved as a first-line treatment for CLL, but only in combination with chlorambucil and specifically for patients who are not candidates for fludarabine-based therapy. It is not considered a universal first-line option. The treating oncologist determines eligibility based on the patient’s overall health, disease stage, and prior treatment history. Patients should consult their healthcare provider to understand whether this combination is appropriate for their individual case.

Can Arzerra cause long-term immune suppression?

Yes. Because ofatumumab depletes B-cells, it can cause prolonged suppression of immune function, which may persist for months after the last dose. This increases the risk of infection, particularly with opportunistic pathogens. Clinicians monitor immunoglobulin levels and infection history throughout and after treatment. Patients with signs of ongoing immunosuppression — such as frequent or severe infections — should report these to their provider, who may recommend additional supportive care.

Are live vaccines safe to receive while taking Arzerra?

Live vaccines are generally contraindicated during Arzerra treatment and for a period afterward, as the drug significantly reduces B-cell counts and blunts the immune response. This makes live vaccines potentially unsafe and less effective. Patients should discuss their vaccination history and any upcoming vaccine needs with their oncologist before starting treatment. Inactivated vaccines may still be used in some cases but should be timed carefully, ideally before initiating therapy when possible.